All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
A meeting on lymphoma Biology by the American Society of Hematology (ASH) took place between 2–5 August 2018, in Chantilly, Virginia. The program was ACCME-accredited and featured a variety of sessions for experts to discuss the unmet needs in the lymphoma community.
Dr Francesc Bosch, University Hospital Vall d’Hebron, Barcelona, is a member of the Lymphoma Hub scientific advisory board and who attended the meeting in August. Dr Bosch provided a summary of the meeting for the Lymphoma Hub capturing the key outcomes of what was discussed.
New technologies: histo-cytometry tech data and data on circulating tumoral DNA was found to be useful for analysis of resistant clones, genotyping tutors, and analysis of the dynamics of ctDNA during treatment, becoming a reliable early (after 2nd cycle) predictor of response to therapy
Targeting therapies: Anthony Letai, discussed potential combinations that increase BCL2 dependency of the tumoral cells, (i.e., adding bortezomib or Azacitidine). Margaret Shipp and Louis Staudt presented the data of the classification of lymphomas based on the gene expression profile and the presence of genetic lesions. These new five subgroups could be of paramount relevance when deciding therapies. Bertrand Nadel presented a comprehensive analysis of single cell RNAseq of normal germinal center cells and follicular lymphomas, demonstrating that there is an enormous inter-patient variation and important intra-patient heterogeneity
Ralf Kuppers presented data on the normal CD30+ cells inside and outside germinal center, and finally, Elias Campo revised the recent data on the activity of Cyclin D1 in the pathogenesis of mantle cell lymphoma
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox